Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus

Hepatology Research

Volumn 47, Issue 11, 2017, Pages 1206-1211

  Seko, Yuya ^a   Sumida, Yoshio ^a   Tanaka, Saiyu ^b   Mori, Kojiroh ^b   Taketani, Hiroyoshi ^a   Ishiba, Hiroshi ^a   Hara, Tasuku ^a   Okajima, Akira ^a   Umemura, Atsushi ^a   Nishikawa, Taichiro ^a   Yamaguchi, Kanji ^a   Moriguchi, Michihisa ^a   Kanemasa, Kazuyuki ^b   Yasui, Kohichiroh ^a   Imai, Shunsuke ^b   Shimada, Keiji ^b   Itoh, Yoshito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Nara City Hospital   (Japan)

Author keywords

dulaglutide; non alcoholic fatty liver disease; transient elastography; type 2 diabetes mellitus

Indexed keywords

AMINOTRANSFERASE; DULAGLUTIDE; HEMOGLOBIN A1C;

AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY COMPOSITION; BODY COMPOSITION ANALYZER; BODY FAT; BODY WEIGHT; CASE STUDY; CLINICAL ARTICLE; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELASTOGRAPH; ENZYME ACTIVITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER STIFFNESS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSIENT ELASTOGRAPHY;

EID: 85006355435     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12837     Document Type: Article

References (14)

1. Hotta N, Nakamura J, Iwamoto Y et al. Causes of death in Japanese diabetics: a questionnaire survey of 18,385 diabetics over a 10-year period. J Diabetes Invest 2010; 1: 66–76.
2. Watanabe S, Hashimoto E, Ikejima K et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015; 50: 364–377.
3. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–2023.
4. Hassan MM, Curley SA, Li D et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938–1946.
5. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355(22): 2297–2307.
6. Cusi K, Orsak B, Bril F et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 2016; 165: 305–315.
7. Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387(10019): 679–690.
8. Eguchi Y, Kitajima Y, Hyogo H et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 2015; 45: 269–278.
9. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–2474.
10. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
11. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.
12. Gupta NA, Mells J, Dunham RM et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584–1592.
13. Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2014; 29: 1470–1476.
14. Dungan KM, Povedano ST, Forst T et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384(9951): 1349–1357.